Millions of people all over the world suffer from diseases, for which there is no known treatment. At the same time, thousands of skilled scientists are working on early research projects, which might one day provide novel therapies for the people in need.
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson’s and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas.
Herantis’ shares are listed on NASDAQ OMX Helsinki First North Finland.